Idiopathic myelofibrosis and pyoderma gangrenosum involving a mutation of Janus kinase 2 (JAK2V617F), showing poor prognosis

Eur J Dermatol. 2013 Apr 1;23(2):256-7. doi: 10.1684/ejd.2013.1956.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Anti-Inflammatory Agents / therapeutic use
  • Colitis, Ulcerative / complications
  • Colitis, Ulcerative / drug therapy
  • Colitis, Ulcerative / genetics
  • Enterococcus
  • Fatal Outcome
  • Humans
  • Janus Kinase 2 / genetics*
  • Male
  • Mutation
  • Pneumonia, Bacterial / microbiology
  • Prednisolone / therapeutic use
  • Primary Myelofibrosis / complications
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / genetics*
  • Prognosis
  • Pyoderma Gangrenosum / complications
  • Pyoderma Gangrenosum / drug therapy
  • Pyoderma Gangrenosum / genetics*

Substances

  • Anti-Inflammatory Agents
  • Prednisolone
  • Janus Kinase 2